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Abstract  
BACKGROUND: Some of the excitatory neurotransmitters including glutamate have been suggested to be 
involved in headache pathophysiology. To our knowledge, there is a lack of publication about flunarizine efficacy 
in chronic tension-type headache (CTTH) treatments and the roles of glutamate in CTTH pathophysiology. 
AIM: This study aimed to investigate the flunarizine effect on serum levels of glutamate and its correlation with 
headache intensity based on the Numeric Rating Scale for pain (NRS) scores in CTTH patients. 
METHOD: In a prospective randomised, double-blind study with pre and post-test design, seventy-three CTTH 
patients were randomly allocated with flunarizine 5 mg, flunarizine 10 mg and amitriptyline 12.5 mg groups. The 
serum levels of glutamate and NRS scores were measured before and after 15-day treatment. 
RESULTS: Flunarizine 5 mg was more effective than flunarizine 10 mg and amitriptyline 12.5 mg in reducing 
serum glutamate levels, whereas amitriptyline 12.5 mg was the most effective in reducing headache intensity. 
There was found nonsignificant, but very weak negative correlation between headache intensity and serum 
glutamate levels after flunarizine 5 mg administration (r = -0.062; P = 0.385), nonsignificant very weak negative 
correlation after flunarizine 10 mg administration (r = -0.007; P = 0.488) and there was found a significant 
moderate positive correlation (r = 0.508; P = 0.007) between headache intensity and serum glutamate levels after 
amitriptyline 12.5 mg administration. 
CONCLUSION: Since there was no significant correlation found between serum glutamate and headache 
intensity after treatment with flunarizine, it is suggested that decreasing of headache intensity after flunarizine 
treatment occurred not through glutamate pathways in CTTH patients. 
 
 
 
 
 
 
Introduction 
 
Headache disorders are one of the most 
common problems seen in the medical practice. 
Among all types of headache disorders, tension-type 
headache (TTH) is the most frequent in adults. 
Epidemiological studies reveal that 20–30% of the 
Asian population suffer from TTH and the global 
prevalence of TTH in the adult population is 42% [1]. 
A hospital-based study in Indonesia reported the 
prevalence of episodic tension-type headache (ETTH) 
and chronic tension-type headache (CTTH) to be 31% 
and 24% respectively [2]. There are no helpful 
investigations in diagnosing TTH so that the definition 
relies exclusively on clinical symptoms [3].  According  
to  the International Classification of Headache 
Disorders, third edition beta version (ICHD-3 beta), 
CTTH is defined as the occurrence of TTH at a 
frequency of ≥15 days per month, with typically 
bilateral, pressing, or tightening in quality, and of mild 
to moderate intensity, lasting hours to days, or 
unremitting. The pain does not worsen with routine 
physical activity but may be associated with mild 
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nausea, photophobia, or phonophobia [4]. Despite its 
high prevalence and socioeconomic impact, our 
understanding of TTH pathogenesis is surprisingly 
limited. One proposed hypothesis is that nociception 
from pericranial muscles, sensitisation of pain 
transmission circuits at the trigeminal nucleus/dorsal 
horn, and dysregulation of central pain modulation 
have each been postulated to play a significant role in 
the pathophysiology of CTTH [5, 6]. 
Glutamate, like serotonin and dopamine, is a 
prominent neurotransmitter in the CNS that mediates 
fast excitatory synaptic neurotransmission via 
ionotropic and metabotropic receptors [7]. Glutamate 
is stored intracellularly inside synaptic vesicles where 
the concentration may be as high as 100 millimolar 
and is inactive until released into the synapse. 
Glutamate is believed to be required to activate the 
trigeminovascular system and central sensitisation. 
Glutamatergic receptors are the molecular mediators 
through which glutamate acts and are found in the 
trigeminovascular system and its structures. The 
activation of NMDA receptors by glutamate has been 
hypothesised to play a role in primary headache 
disorders. Pain perception in CTTH as one of primary 
headache disorders might be activated through these 
pathways. By blocking NMDA receptors and, 
therefore, inhibiting these pathways, memantine could 
prevent primary headaches [8]. Previous studies 
reported that plasma glutamate levels monitoring in 
migraine patients might serve as a biomarker of 
response to treatments and as an objective measure 
of disease status [9]. 
Flunarizine, a long-acting calcium channel 
blocker, was originally introduced in the 1970s for the 
treatment of occlusive vascular diseases. The 
mechanism of action of flunarizine in a migraine is 
unclear, although its calcium and dopaminergic 
antagonism may offer some insights into possible 
subcortical brain targets. It has been reported that 
flunarizine can also cause inhibition of transmission 
along the trigeminovascular system [10]. Several 
studies have demonstrated its efficacy in migraine 
prophylaxis in adults [11]. However, to our knowledge, 
there is lack of publications about its efficacy in CTTH 
treatment.  
We aim to see the flunarizine effect on serum 
levels of glutamate and its correlation with headache 
intensity based on the Numeric Rating Scale for pain 
(NRS) scores in CTTH patients. 
 
 
Materials and Methods 
 
Subjects and procedures 
We studied 73 subjects (Table 1) suffering 
from CTTH according to the International 
Classification of Headache Disorders, 2nd edition 
(ICHD-II) criteria [12]. Chronic tension-type headache 
patients were recruited among those attended the 
outpatient clinic of the Adam Malik General Hospital 
Medan, Puteri Hijau Hospital and Medan Johor 
Primary Health Center Medan, Indonesia, during April 
and August 2016. Seventy-three patients out of 
ninety-five initially recruited had completed the study 
protocol until the end of the study and 22 drop out. Of 
22 subjects drop out, one female patient discontinued 
consuming the prophylactic drug given due to an 
allergic reaction; twenty-one of them did not come 
back for the second blood samples. They were 
randomly allocated into three interventional groups to 
receive one of the following drugs for 15 days 
(flunarizine 5 mg/day, flunarizine 10 mg/day and 
amitriptyline12.5 mg/day). We included both male and 
female patients, between 18-65 years old. We 
excluded CTTH patients receiving or having received 
a prophylactic treatment in the previous 4-weeks, 
patients with neurological deficits related to his/her 
headache, serious somatic or psychiatric diseases 
including depression, extrapyramidal disorders, 
chronic obstructive pulmonary disease (COPD), 
bronchial asthma, heart failure, diabetes mellitus, 
cardiovascular disease, malignancy, pregnancy, 
lactation and hypersensitive to flunarizine or 
amitriptyline. 
Table 1: Chronic tension-type headache patient characteristics 
Characteristics All Patients Flunarizine 5 mg 
group (N = 25) 
Flunarizine 10 
mg 
group (N=25) 
Amitriptyline 
12.5 mg group 
(N=23) 
N (%)  73 (100) 25(34.2) 25(34.2) 23(31.5) 
Gender     
Male (%) 13 (17.8) 4 (16) 5 (20) 4 (17.4) 
Female (%) 60 (82.2) 21 (84) 20 (80) 19 (82.6) 
Mean age ± 
S.D. (years)  
 
44.6 ± 13.47 
 
41.56 ± 14.90 
 
45.12 ± 12.17 
 
47.35 ± 13.06 
Marital Status     
Married N(%) 57 (78.1) 17 (68) 22 (88) 18 (78.3) 
Single N(%) 16 (21.9) 8 (32) 3 (12) 5 (21.7) 
History of CTTH 
(years, mean ± 
S.D) 
 
4.78 ± 2.29 
 
4.76 ± 2.33 
 
4.80 ± 2.08 
 
4.78 ± 2.56 
Psychiatric 
disorders 
None None None None 
N= number of patients; S.D = standard deviation; CTTH= chronic tension-type headache. 
 
All subjects agreed to participate and signed 
informed consent voluntarily after receiving a detailed 
description of the study procedures and purposes. 
The study was approved by the Health Research 
Ethical Committee of North Sumatera/RSUP H Adam 
Malik Medan, c/o Medical School, Universitas 
Sumatera Utara. Patients’ characteristics were 
recorded by medical examination, and headache 
intensity was measured using the Numeric Rating 
Scale for Pain (NRS) scores. The NRS scores consist 
of 4 levels of pain perception (0 = no pain, 1-3 = mild 
pain, 4-7 = moderate pain and 8-10 = severe pain). 
Chronic tension-type headache patients were studied 
before and after 15-day treatment. Venous blood 
samples for the assay of glutamate concentration 
were taken after data collection completed. 
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Assay of glutamate 
Blood samples were collected in vacutainer 
tubes. Serum separation was isolated by 
centrifugation at 1000 g over 15 minutes. The serum 
samples should always be pre-diluted 1:5 (100 µl 
serum + 400 µl water) and stored at 2-80C until the 
time of analysis. 
Glutamate concentrations in serum samples 
were analysed using Glutamate ELISA Kit (KA1909-
Abnova) according to manufacturers’ instructions and 
Chemwell 2910 analyser. There are three steps of the 
glutamate assay procedures: extraction, derivatisation 
and ELISA. Extraction procedures were performed 
manually, whereas derivatisation and ELISA were 
done robotically using Chemwell 2910 analyser. Limit 
of detection of Glutamate Elisa Kit (KA1909-Abnova) 
is 0.3 µg/ml or equals 2.04 µmol/L. 
 
Data analysis 
Serum glutamate levels and NRS scores 
before and after 15-days treatment were analysed by 
using T-test for paired data. Kruskal-Wallis test 
followed by post hoc analysis with Mann-Whitney test 
was used to determine the most significant treatment 
effects between groups. All data were expressed as 
mean ± S.D. P < 0.05 was considered to be significant 
 
 
Results 
 
Characteristics of CTTH patients in this study 
are based on sociodemographic characteristics that 
include gender, age, history of CTTH and psychiatric 
evaluation. Majority of patients were female, married 
and the mean history of CTTH (4.78 ± 2.29) years. 
None of the patients has a psychiatric disorder. 
Both serum glutamate levels and NRS scores 
were significantly lower after 15 days treatment with 5 
mg and 10 mg flunarizine as well as with 12.5 mg 
amitriptyline. Serum glutamate decrement levels 
continued to be significantly higher in flunarizine 5 mg 
group (1.19 ± 1.13 µg/L) than in flunarizine 10 mg 
group ( 0.75 ± 0.60 µg/L) and amitriptyline 12.5 mg 
group (0.20 ± 0.23 µg/L) (P < 0.001, Kruskal-Wallis 
test followed by Mann-Whitney post hoc testing). 
Decreased NRS score was found significantly in all 
three groups (flunarizine 5 mg, 1.12 ± 0.78 µg/L; 
flunarizine 10 mg, 2.48 ± 0.65 µg/L and amitriptyline 
12.5 mg, 3.35 ± 0.71 µg/L) (P < 0.001, Kruskal-Wallis 
test followed by Mann-Whitney post hoc testing) 
compared before and after treatment (Table 2). 
Table 2: Serum concentration (Mean ± S.D.) of glutamate (µg/L) 
and NRS score 
Drugs Serum Glutamate P NRS Score P 
Before After Before After 
Flunarizine      
5 mg 12.04 ± 
3.02 
10.86 ± 
2.89 
<0.001 4.64 ± 
0.64 
3.52 ± 
0.65 
<0.001 
Flunarizine      
10 mg 11.60 ± 
2.38 
10.86 ± 
2.49 
<0.001 4.92 ± 
0.57 
2.44 ± 
0.65 
<0.001 
Amitriptyline      
12.5 mg 11.89 ± 
1.76 
11.69 ± 
1.81 
<0.001 5.09 ± 
0.51 
1.74 ± 
0.62 
<0.001 
Before vs. after 15-day treatment: P < 0.05 (t - test for paired data) 
 
The most significant decrement of NRS was 
found in amitriptyline 12.5 mg group, whereas the 
most decrement of serum glutamate concentration 
was found in flunarizine 5 mg group. (Figure 1 and 
Figure 2). 
 
Figure 1: Serum concentration decrement (Mean ± S.D.) of 
glutamate (µg/L) in CTTH patients, before and after 15-day of 
treatment 
 
After flunarizine 5 mg administration the NRS 
scores showed very weak negative and non-
significant correlation (R = - 0.062; P = 0.385) with 
serum glutamate concentration. 
 
 
Figure 2: Numeric Rating Scale for Pain (NRS Scores) decrement 
(mean ± S.D.) in  CTTH patients, before and after 15-day treatment 
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The NRS scores also showed very weak 
negative and non-significant correlation (R = - 0.007; 
P = 0.488) after flunarizine 10 mg administration. 
Moderate positive correlation (R = 0.508; P = 0.007) 
was found between NRS scores and serum glutamate 
concentration after amitriptyline 12.5 mg 
administration (Table 3). 
Table 3: Correlation between NRS scores and serum Glutamate 
concentration (g/L) after treatment with Flunarizine 5 mg, 
Flunarizine 10 mg and Amitriptyline 12.5 mg 
  NRS SCORE AFTER TREATMENT 
 Flunarizine 5 mg Flunarizine 10 mg Amitriptyline 12.5 
mg 
 
R P N R P N R P N 
Glutamate 
(g/L) 
- 0.062 0.385 25 - 0.007 0.488 25 0.508 0.007 23 
NRS = Numeric Rating Scale for pain (Headache Intensity); r = correlation; P = 
significance; N = number of patients. 
 
 
 
Discussion 
 
In this study, the administration of flunarizine 
for 15 days was followed by a significant reduction of 
serum glutamate levels and headache intensity in 
CTTH patients. The relationship between the 
reduction of serum glutamate concentration and 
headache intensity after treatment with flunarizine in 
the present study was more likely an association than 
a causal one since there was no significant correlation 
found between serum glutamate levels and headache 
intensity in CTTH patients. 
The mechanism which makes most 
prophylactic drugs effective in CTTH is not completely 
understood. Our results support the hypothesis that 
there might be a commonality or overlap of a signal 
barrage to the spinal or brainstem in chronic pain or 
chronic headache states. The glutamate system might 
be the point of amplification or reinforcement of the 
pain transmission cascade in these clinical conditions. 
Flunarizine, a calcium channel blocker, can cross 
blood brain barrier and could inhibit the release of 
glutamate just blocking the voltage-dependent calcium 
channel. It blocks calcium influx so that suppression of 
neuron hyper-excitability results in reducing headache 
intensity [6, 13, 14]. In this study, there were found 
significant reductions of serum glutamate levels 
followed by decreased headache intensity after 
flunarizine treatment. However, there was found non-
significant very weak negative correlation (r = -0.062; 
P = 0.385) between serum glutamate and headache 
intensity. It revealed that decrease headache intensity 
after flunarizine treatment occurred not through the 
reduction of serum glutamate levels in CTTH patients. 
After amitriptyline treatment, there were found 
significant reductions of serum glutamate levels 
followed by decreased headache intensity. There was 
also found moderate positive correlations (r = 0.508; P 
= 0.007) between serum glutamate and headache 
intensity. It revealed that the decreased headache 
intensity after amitriptyline treatment might be related 
to serum glutamate reduction. Amitriptyline blocks the 
neuronal reuptake of serotonin and noradrenaline, 
although this is not the only mode of action of its 
antinociceptive properties. N-methyl- D-aspartate 
(NMDA) receptor antagonism and blockade of 
muscarinic receptors and ion channels may play a 
role as well [15, 16].  
Accumulated evidence has demonstrated that 
amitriptyline likely affects multiple receptors 
associated with pain modulation. For example, 
amitriptyline has been found to interact with opioids 
receptors, to inhibit the cellular uptake of adenosine, 
and to block N-methyl-D-aspartate (NMDA) receptors 
[15]. 
The reduction of serum glutamate levels after 
15-day flunarizine treatment reveals that flunarizine 
influence the glutamatergic transmission in the 
pathogenesis of a tension-type headache. Although 
glutamate is thought not to readily cross the blood-
brain barrier, the levels of glutamate in the blood are 
positively correlated with the cerebrospinal fluid (CSF) 
levels of glutamate in humans. McGale et al. 1977 
reported that the concentration of 13 amino acids in 
CSF had been shown to be directly related to the 
plasma concentration [17]. Alfredsson et.al. 1988 
found that the serum and CSF levels of glutamate 
were positively correlated (R = 0.67, P < 0.05) [18]. 
Thus, the peripheral glutamate levels can be 
postulated to reflect the glutamate levels in the brain 
per se. In fact, increased plasma levels of glutamate 
have been reported in some neuropsychiatric 
disorders, such as epilepsy, Alzheimer’s disease and 
amyotrophic lateral sclerosis, in which glutamate 
excitotoxicity is thought to play a role in the 
pathophysiology [19-21].  
Our results have shown that decreased serum 
glutamate levels followed by reduction of headache 
intensity in the treatment with amitriptyline in CTTH 
patients. It is suggested that the reduction of 
headache intensity in CTTH patients after amitriptyline 
administration occurs through the pathway of 
decreasing serum glutamate since there was 
significant correlation found between serum glutamate 
levels and pain intensity in CTTH patients. 
Conversely, since there was no significant correlation 
found between serum glutamate and headache 
intensity after treatments with flunarizine, it is 
suggested that decreasing of headache intensity 
occur not through glutamate pathways. However, our 
data must be interpreted cautiously, considering the 
limited size of the sample.  
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